样式: 排序: IF: - GO 导出 标记为已读
-
Are NOACs always the best strategy in elderly AF patients? Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-29 Moritake Iguchi,Juan Tamargo,Koji Hasegawa
-
First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-29 Basil S Lewis
-
The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristics. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-28 Anna Meta Dyrvig Kristensen,John Munkhaugen,Sigrun Halvorsen,Michael Hecht Olsen,Arnhild Bakken,Thomas Steen Gyldenstierne Sehested,Vidar Ruddox,Theis Lange,Morten Wang Fagerland,Christian Torp-Pedersen,Eva Prescott,Dan Atar
AIM The evidence for beta-blocker therapy after myocardial infarction (MI) is randomized trials conducted more than 30 years ago, and the continued efficacy has been questioned. DESIGN AND METHODS The ongoing Danish (DANBLOCK) and Norwegian (BETAMI) randomized beta-blocker trials are joined to evaluate the effectiveness and risks of long-term beta-blocker therapy after MI. Patients with normal or mildly
-
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-28 Nam Hoon Kim,Ji Yoon Kim,Jimi Choi,Sin Gon Kim
AIMS Omega-3 fatty acids and fenofibrates have shown some beneficial cardiovascular effects; however, their efficacy has not been compared. This study aimed to compare the effectiveness of currently available omega-3 fatty acids and fenofibrate for reducing major adverse cardiovascular events (MACE). METHODS AND RESULTS From a nationwide population-based cohort in South Korea (2008-2019), individuals
-
Ticagrelor Enhances the Cardioprotective Effects of Ischemic Preconditioning in Stable Patients Undergoing Percutaneous Coronary Intervention: the TAPER-S Randomized Study. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-24 Domenico D'Amario,Mattia Galli,Attilio Restivo,Francesco Canonico,Rocco Vergallo,Stefano Migliaro,Carlo Trani,Francesco Burzotta,Cristina Aurigemma,Renzo Laborante,Enrico Romagnoli,Francesca Francese,Ilaria Ceccarelli,Josip A Borovac,Dominick J Angiolillo,Barbara Tavazzi,Antonio M Leone,Filippo Crea,Giuseppe Patti,Italo Porto
BACKGROUND Ticagrelor improves clinical outcomes in patients with acute coronary syndrome compared with clopidogrel. Ticagrelor also inhibits cell uptake of adenosine and has been associated with cardioprotective effects in animal models. We sought to investigate the potential cardioprotective effects of ticagrelor, as compared with clopidogrel, in stable patients undergoing percutaneous coronary intervention
-
Effectiveness and safety of direct oral anticoagulation versus warfarin in frail patients with atrial fibrillation. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-22 Mette Søgaard,Anne Gulbech Ording,Flemming Skjøth,Torben Bjerregaard Larsen,Peter Brønnum Nielsen
AIMS Although frail patients with atrial fibrillation (AF) carry a high risk of stroke and treatment-related bleeding complications, evidence for the safety and effectiveness of anticoagulation remain sparse. This study investigated the effectiveness and safety of DOAC versus warfarin in frail AF patients. METHODS AND RESULTS Nationwide registry-based cohort study including 32048 anticoagulation naïve
-
Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-20 Chiara Oriecuia,Daniela Tomasoni,Isabella Sala,Giovanni Battista Bonfioli,Marianna Adamo,Cristina Gussago,Carlo Mario Lombardi,Matteo Pagnesi,Gianluigi Savarese,Marco Metra,Claudia Specchia
BACKGROUND Sodium Glucose Co-Transporter 2 Inhibitors (SGLT2i) are one of the cornerstones of heart failure (HF) therapy. Whilst benefits in terms of HF hospitalizations and death are well established, their impact on quality-of-life (QoL) has not been systematically investigated. OBJECTIVE This systematic review and meta-analysis aims to evaluate the impact of SGLT2i treatment on QoL in patients with
-
The potential future role of extensive lipid lowering in ACS patients with the use of PCSK9 inhibitors: Early bird catches the worm. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-17 Kyriakos Dimitriadis,Nikolaos Pyrpyris,Konstantinos Tsioufis
-
Impact of Ethnicity on Antiplatelet Treatment Regimens for Bleeding Reduction in Acute Coronary Syndromes: A Systematic Review and Pre-specified Subgroup Meta-analysis. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-13 Mattia Galli,Renzo Laborante,Giovanni Occhipinti,Andea Zito,Luigi Spadafora,Giuseppe Biondi-Zoccai,Roberto Nerla,Fausto Castriota,Domenico D'Amario,Davide Capodanno,Young-Hoon Jeong,Takeshi Kimura,Roxana Mehran,Dominick J Angiolillo
AIM Randomized controlled trials (RCTs) testing bleeding reduction strategies using antiplatelet treatment regimens (BRATs) in acute coronary syndromes (ACS) have shown promising results, but the generalizability of these findings may be significantly influenced by the ethnicity of the patients enrolled, given that East Asian (EA) patients show different ischemic-bleeding risk profile compared to non-EA
-
Low-dose aspirin and incident atrial fibrillation in healthy older individuals: a post-hoc analysis of the ASPREE Trial. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-10 J Ball,J T Neumann,A M Tonkin,P Kirchhof,B Freedman,A Brodtmann,C Reid,M R Nelson,L J Beilin,S Fitzgerald,D Stub,R L Woods,J J McNeil
-
Combination therapy with moderate-intensity atorvastatin and ezetimibe versus high-intensity atorvastatin monotherapy in patients treated with percutaneous coronary intervention in practice: assessing RACING generalizability. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-10 Seung-Jun Lee,Jae Hong Joo,Sohee Park,Choongki Kim,Dong-Woo Choi,Yong-Joon Lee,Sung-Jin Hong,Chul-Min Ahn,Jung-Sun Kim,Byeong-Keuk Kim,Young-Guk Ko,Donghoon Choi,Yangsoo Jang,Chung-Mo Nam,Myeong-Ki Hong
AIMS Using rosuvastatin, the RACING (randomized comparison of efficacy and safety of lipid-lowering with statin monotherapy versus statin/ezetimibe combination for high-risk cardiovascular diseases) trial showed the beneficial effects of combining moderate-intensity statin with ezetimibe compared with high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease. This study
-
What is optimal DAPT duration after PCI? Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-09 Hiroki Shiomi,Koji Hasegawa,Koh Ono
-
Risk of hyperkalemia in patients with type 2 diabetes mellitus prescribed with SGLT2 versus DPP-4 inhibitors. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-06 Mei-Zhen Wu,Tiew-Hwa Katherine Teng,Christopher Tze-Wei Tsang,Yap-Hang Chan,Chi-Ho Lee,Qing-Wen Ren,Jia-Yi Huang,Iok-Fai Cheang,Yi-Kei Tse,Xin-Li Li,Xin Xu,Hung-Fat Tse,Carolyn S P Lam,Kai-Hang Yiu
AIMS To investigate the risk of hyperkalemia in new users of sodium-glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors among patients with type 2 diabetes mellitus (T2DM). METHODS AND RESULTS Patients with T2DM who commenced treatment with an SGLT2 or DPP-4 inhibitor between 2015 and 2019 were collected. A multivariable Cox proportional hazards analysis was
-
FLOW trial stopped early due to evidence of renal protection with semaglutide. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-02 Felice Gragnano,Vincenzo De Sio,Paolo Calabrò
-
2023 ESC Guidelines on ACS: what is new in antithrombotic therapy? Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-02 Mattia Galli,Felicita Andreotti,Pierre Sabouret,Felice Gragnano
-
What's new in pharmacotherapy at ESC Congress 2023? Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-02 Felice Gragnano,Paolo Calabrò,Mattia Galli
-
Impact of transfusion strategy on platelet aggregation and biomarkers in myocardial infarction patients with anemia. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-02 Johanne Silvain,Benoit Lattuca,Etienne Puymirat,Gregory Ducrocq,Jean-Guillaume Dillinger,Thibault Lhermusier,Niki Procopi,Marine Cachanado,Elodie Drouet,Helene Abergel,Nicolas Danchin,Gilles Montalescot,Tabassome Simon,Philippe Gabriel Steg
BACKGROUND Higher rates of thrombotic events have been reported in myocardial infarction (MI) patients requiring blood transfusion. The impact of blood transfusion strategy on thrombosis and inflammation is still unknown. OBJECTIVE To compare the impact of a liberal vs. a restrictive transfusion strategy on P2Y12 platelet reactivity and biomarkers in the multicentric randomized REALITY trial. METHODS
-
P2Y12 inhibition in high bleeding risk patients: making the right decision in a complex setting. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-02 Kyriakos Dimitriadis,Nikolaos Pyrpyris,Konstantinos Aznaouridis,Konstantinos Tsioufis
-
Platelet activation and endothelial dysfunction biomarkers in acute coronary syndrome: the impact of PCSK9 inhibition. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-02 Efthymios Ziogos,Stephen P Chelko,Tarek Harb,Morgan Engel,Michael A Vavuranakis,Maicon Landim-Vieira,Elise M Walsh,Marlene S Williams,Shenghan Lai,Marc K Halushka,Gary Gerstenblith,Thorsten M Leucker
AIMS Platelet activation and endothelial dysfunction contribute to adverse outcomes in patients with acute coronary syndromes (ACS). The goals of this study were to assess the impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition on markers of platelet activation and endothelial dysfunction in ACS patients and the interaction among PCSK9, platelets, and endothelial cells (ECs)
-
Factor XIa inhibitors: collecting the clinical evidence. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-01 Basil S Lewis,Koji Hasegawa
-
Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism in patients with inflammatory joint disease - results from the nationwide Norwegian Cardio-rheuma registry. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-10-25 Eirik Ikdahl,Silvia Rollefstad,Amirhossein Kazemi,Sella A Provan,Trine-Lise Larsen,Anne Grete Semb
AIMS Patients with inflammatory joint diseases (IJD), including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) have increased rates of pulmonary embolism (PE). Non-steroidal anti-inflammatory drugs (NSAIDs) use is associated with PE in the general population. Our aim was to evaluate the association between NSAIDs use and PE in IJD patients. METHODS AND RESULTS
-
Anticoagulation in Cancer-associated Thrombosis: How Long Should the Therapy Be? Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-10-12 Wei Xiong,Stefan Agewall,Yugo Yamashita
-
Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-10-09 Wayne C Zheng,William Chan,Anthony Dart,James A Shaw
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality worldwide. Even with excellent control of LDL-C levels, adverse cardiovascular events remain a significant clinical problem worldwide, including among those without any traditional ASCVD risk factors. It is necessary to identify novel sources of residual risk and to develop targeted strategies that address
-
A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-10-06 Joanna Osmanska,Katriona Brooksbank,Kieran F Docherty,Stacy Robertson,Kirsty Wetherall,Alex McConnachie,Jerry Hu,Roy S Gardner,Andrew L Clark,Iain B Squire,Paul R Kalra,Pardeep S Jhund,Pieter Muntendam,John J V McMurray,Mark C Petrie,Ross T Campbell
AIMS Subcutaneous (SC) furosemide has potential advantages over intravenous (IV) furosemide by enabling self-administration or administration by a lay caregiver, such as facilitating early-discharge, preventing hospitalizations and in palliative care. A high concentration, pH neutral furosemide formulation has been developed for SC administration via a small patch-infusor pump. We aimed to compare
-
Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-10-03 Maxim Grymonprez,Laura Carnoy,Andreas Capiau,Koen Boussery,Els Mehuys,Tine L De Backer,Stephane Steurbaut,Lies Lahousse
AIMS The clinical relevance of common pharmacokinetic interactions with non-vitamin K antagonist oral anticoagulants (NOACs) often remains unclear. Therefore, the impact of P-glycoprotein (P-gp) and CYP3A4 inhibitors and inducers on clinical outcomes in NOAC-treated patients with atrial fibrillation (AF) was investigated. METHODS AND RESULTS AF patients were included between 2013-2019 using Belgian
-
GLP-1 receptor agonists: new game changing drugs in patients with heart failure with preserved ejection fraction and obesity. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-09-30 Eri Toda Kato,Basil S Lewis,Koh Ono
-
Predictive value of the thrombotic risk criteria proposed in the 2023 ESC guidelines for the management of ACS: insights from a large PCI registry. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-09-23 Alessandro Spirito,Davide Cao,Samantha Sartori,Ashutosh Sharma,Kenneth F Smith,Birgit Vogel,Karim Kamaleldin,Anoop N Koshy,Yihan Feng,David Power,Usman Baber,Parasuram Melarcode-Krishnamoorthy,Samin K Sharma,Annapoorna Kini,George Dangas,Roxana Mehran
AIM To assess the value of the thrombotic risk criteria proposed in the 2023 guidelines of the European Society of Cardiology (ESC) for the management of acute coronary syndrome (ACS) to predict the ischemic risk after percutaneous coronary intervention (PCI). METHODS AND RESULTS Consecutive patients with acute or chronic coronary syndrome undergoing PCI at a large tertiary-care center from 2014 to
-
Balancing the risks of bleeding and ischemia in myocardial infarction patients at high bleeding risk. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-09-22 J Tjerkaski,T Jernberg,K Szummer
-
Effects of Renin-Angiotensin system blockers on outcomes from COVID-19: A systematic review and meta-analysis of randomised controlled trials. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-09-22 Matthew M Y Lee,Toru Kondo,Ross T Campbell,Mark C Petrie,Naveed Sattar,Scott D Solomon,Muthiah Vaduganathan,Pardeep S Jhund,John J V McMurray
BACKGROUND AND AIMS Randomised controlled trials (RCTs) have assessed the effects of renin-angiotensin system (RAS) blockers in adults with COVID-19. This meta-analysis provides estimates of the safety and efficacy of treatment with (versus without) RAS blockers from these trials. METHODS PubMed, Web of Science, and ClinicalTrials.gov were searched (March 1-April 12, 2023). Event/patient numbers were
-
Unexplored horizons on sex bias and progression of heart failure with preserved ejection fraction. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-09-20 Giuditta Benincasa,Claudio Napoli
-
Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-09-20 David Mutschlechner,Maximilian Tscharre,Kurt Huber,Thomas Gremmel
AIMS Reduction of low-density lipoprotein cholesterol (LDL-C) decreases cardiovascular mortality and morbidity. Bempedoic acid represents a promising novel lipid-modifying agent for patients who cannot reach guideline recommended LDL-C goals or statin-intolerant patients, but data on safety and cardiovascular outcomes are limited. We therefore aimed to systematically review randomized controlled trials
-
What is new in the 2023 AHA/ACC Multisociety guideline on Chronic coronary Disease? Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-09-18 Felice Gragnano,Vincenzo De Sio,Paolo Calabrò
-
Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational study. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-08-31 M Bonaca,E Lesén,E Giannitsis,J Hedberg,T Jernberg,D Lambrelli,M Duong,A P Maggioni,A Ariza-Solé,J Ten Berg,R F Storey
BACKGROUND Guidelines recommend extended dual antiplatelet therapy (DAPT), including ticagrelor 60 mg twice daily, in high-risk post myocardial infarction (MI) patients who have tolerated 12 months and are not at high bleeding risk. The real-world utilization and bleeding and ischemic outcomes associated with long-term ticagrelor 60 mg in routine clinical practice have not been well described. METHODS
-
External validity of the PRECISE-DAPT score in patients undergoing PCI: a systematic review and meta-analysis. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-08-26 Andrea Raffaele Munafò,Claudio Montalto,Marco Franzino,Lorenzo Pistelli,Gianluca Di Bella,Marco Ferlini,Sergio Leonardi,Fabrizio D' Ascenzo,Felice Gragnano,Jacopo A Oreglia,Fabrizio Oliva,Luis Ortega-Paz,Paolo Calabrò,Dominick J Angiolillo,Marco Valgimigli,Antonio Micari,Francesco Costa
AIMS To summarise the totality of evidence validating the Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy (PRECISE-DAPT) score, ascertaining its aggregate discrimination and validation power in multiple population subsets. METHODS AND RESULTS We searched electronic databases from 2017 (PRECISE-DAPT proposal) up to March 2023 for studies
-
Platelet inhibition with orodispersible ticagrelor in acute coronary syndromes according to morphine use: the TASTER study final results. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-08-17 Guido Parodi,Filippo Dossi,Mario Raccis,Giuseppe Talanas,Enrico Mura,Roberta Siciliano,Simona Guarino,Alessandro Marini,Paolo Franca,Pier Sergio Saba,Giuseppe D Sanna,Mario E Canonico
AIM To date, it is still unknown whether orodispersible tablet (ODT) ticagrelor might represent a suitable way to reach a proper antiaggregation in acute coronary syndrome (ACS) patients receiving morphine. Aim of the present study was to evaluate platelet inhibition with 180 mg ticagrelor loading dose (LD) administered as ODT compared with standard coated tablet ticagrelor formulation in ACS patients
-
Clinical Outcomes in Elderly Atrial Fibrillation Patients at Increased Bleeding Risk Treated with Very-Low-Dose versus Regular-Dose Non-Vitamin K Antagonist Oral Anticoagulants: a Nationwide Cohort Study. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-08-14 Yi-Hsin Chan,Tze-Fan Chao,Shao-Wei Chen,Hsin-Fu Lee,Pei-Ru Li,Yung-Hsin Yeh,Chi-Tai Kuo,Lai-Chu See,Gregory Y H Lip
AIMS The ELDERCARE-AF trial showed that edoxaban at a very-low-dosage (VLD) of 15 mg/day was more effective than a placebo at preventing stroke/systemic embolism without significantly increasing the risk of serious bleeding. We aimed to compare the effectiveness and safety for VLD non-vitamin K antagonist oral anticoagulants (NOACs) (edoxaban 15 mg once daily, dabigatran 110 or 150 once daily, apixaban
-
Post-Diagnostic Statin Use and its Association with Cancer Recurrence and Mortality in Breast Cancer Patients: A Systematic Review and Meta-analysis. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-08-10 Vikash Jaiswal,Vibhor Agrawal,Song Peng Ang,Marina Saleeb,Angela Ishak,Maha Hameed,Kripa Rajak,Kriti Kalra,Akash Jaiswal
BACKGROUND Statins are widely acknowledged for their application in patients with hypercholesterolemia to reduce cardiovascular morbidity and mortality. More recently, their potential to exert pleiotropic effects, particularly in impeding the proliferation of neoplastic cells, has attracted considerable attention. Prior studies have demonstrated that statins may mitigate cancer progression and micrometastasis
-
Bioinformatic platforms for clinical stratification of natural history of atherosclerotic cardiovascular diseases. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-08-10 Giuditta Benincasa,Rosa Suades,Teresa Padrò,Lina Badimon,Claudio Napoli
Although bioinformatic methods gained a lot of attention in the latest years, their use in real-world studies for primary and secondary prevention of atherosclerotic cardiovascular diseases (ASCVD) is still lacking. Bioinformatic resources have been applied to thousands of individuals from the Framingham Heart Study as well as health care-associated biobanks such as the UK Biobank, the Million Veteran
-
Atrial fibrillation has gone from a boring disease to a very hot condition. Why is that? Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-07-29
-
The Effect of SGLT2 Inhibitors on the Endothelium and the Microcirculation: From Bench to Bedside and Beyond. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-07-27 Kyriakos Dimitriadis,Eleni Adamopoulou,Nikolaos Pyrpyris,Athanasios Sakalidis,Ioannis Leontsinis,Eleni Manta,Emmanouil Mantzouranis,Eirini Beneki,Stergios Soulaidopoulos,Dimitrios Konstantinidis,Christos Fragkoulis,Konstantina Aggeli,Konstantinos Tsioufis
The beneficial cardiovascular effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors irrespective of the presence of diabetes mellitus are nowadays well established and they already constitute a significant pillar for the management of heart failure, irrespective of the ejection fraction. The exact underlying mechanisms accountable for these effects, however, remain largely unknown. The direct
-
Bleeding risk and P2Y12 inhibitors in all-comer patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention: a single-centre cohort study. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-02 Mia Ravn Jacobsen,Reza Jabbari,Thomas Engstrøm,Erik Lerkevang Grove,Charlotte Glinge,Frants Pedersen,Lene Holmvang,Lars Køber,Christian Torp-Pedersen,Michael Maeng,Karsten Veien,Phillip Freeman,Mette Gitz Charlot,Henning Kelbæk,Rikke Sørensen
AIMS To characterize and follow patients with ST-segment elevation myocardial infarction (STEMI) at high bleeding risk (HBR) according to the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score, and to examine the use of P2Y12 inhibitors and the subsequent risk of major adverse cardiovascular events (MACE) and bleeding
-
The effect of discontinuing beta-blockers after different treatment durations following acute myocardial infarction in optimally treated, stable patients without heart failure: a Danish, nationwide cohort study. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-09-20 Andrim Halili,Anders Holt,Talip E Eroglu,Saranda Haxha,Bochra Zareini,Christian Torp-Pedersen,Casper N Bang
AIMS We studied the effect of discontinuing beta-blockers following myocardial infarction in comparison to continuous beta-blocker use in optimally treated, stable patients without heart failure. METHODS AND RESULTS Using nationwide registers, we identified first-time myocardial infarction patients treated with beta-blockers following percutaneous coronary intervention or coronary angiography. The
-
Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-09-20 Morten Schmidt,Jesper Hallas,Martin Thomsen Ernst,Anton Pottegård
AIMS It is unknown whether the cardiovascular risks associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs) shortly after first-time myocardial infarction (MI) or heart failure (HF) differ between patients continuing and initiating use. METHODS AND RESULTS Using nationwide health registries, we conducted a cohort study of all patients with first-time MI or HF during 1996-2018 (n =
-
The year in cardiovascular pharmacotherapy 2022: landmark evidence at a glance. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-09-20 Felice Gragnano,Vincenzo De Sio,Paolo Calabrò
-
Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-09-20 Johan E Larsson,Cæcilie Stilling Denholt,Jens Jakob Thune,Anna Axelsson Raja,Emil Fosbøl,Morten Schou,Lars Køber,Olav Wendelboe Nielsen,Finn Gustafsson,Søren L Kristensen
BACKGROUND The mineralocorticoid receptor antagonists (MRAs) eplerenone and spironolactone are beneficial in heart failure with reduced ejection fraction (HFrEF), but have not been prospectively compared. We compared clinical outcomes, daily dosages, and discontinuation rates for the two drugs in a nationwide cohort. METHODS We identified all patients with HFrEF in the period 2016-2020, who were alive
-
Antidiabetic drugs and hypoglycaemia risk in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-07-29 Katarzyna Nabrdalik,Hanna Kwiendacz,Gregory Y H Lip
-
Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease? Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-09-20 Heinz Drexel,Juan Tamargo,Juan Carlos Kaski,Basil S Lewis,Christoph H Saely,Peter Fraunberger,Dobromir Dobrev,Maki Komiyama,Thomas Plattner,Stefan Agewall,Koji Hasegawa
Despite the atherosclerotic cardiovascular disease (ASCVD) risk reduction achieved by low-density lipoprotein cholesterol (LDL-C) lowering therapy, residual ASCVD risk still exists. Previous epidemiological studies have suggested high plasma triglyceride (TG) levels as a risk factor or risk marker for ASCVD independent of LDL-C levels. In this review, we highlighted the underlying pathophysiology of
-
Statin therapy reduces dementia risk in atrial fibrillation patients receiving oral anticoagulants. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-07-29 Moo Hyun Kim,Song Lin Yuan,Kwang Min Lee,Xuan Jin,Zhao Yan Song,Jong-Sung Park,Young-Rak Cho,Kyunghee Lim,Sung-Cheol Yun,Michael S Lee,Sun Young Choi
AIMS Atrial fibrillation (AF) is linked to an increased risk of dementia, even in stroke-free patients. The impact of statin therapy on dementia risk is unclear in AF patients receiving oral anticoagulant (OAC) (vitamin K antagonist and direct-acting OAC). We sought to investigate the impact of statin therapy on dementia risk in AF patients receiving OAC. METHODS AND RESULTS Using the Korean National
-
Comparison between ticagrelor and clopidogrel in myocardial infarction patients with high bleeding risk. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-02 Jonathan Tjerkaski,Tomas Jernberg,Joakim Alfredsson,David Erlinge,Stefan James,Bertil Lindahl,Moman Aladdin Mohammad,Elmir Omerovic,Dimitrios Venetsanos,Karolina Szummer
AIMS Ticagrelor is associated with a lower risk of ischemic events than clopidogrel. However, it is uncertain whether the benefits of more intensive anti-ischemic therapy outweigh the risks of major bleeding in patients who have a high bleeding risk (HBR). Therefore, this study compared ticagrelor and clopidogrel in myocardial infarction (MI) patients with HBR. METHODS AND RESULTS This study included
-
A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-09-20 Margherita Bigossi,Cyrielle Maroteau,Adem Y Dawed,Alasdair Taylor,Sundararajan Srinivasan,Alaa' Lufti Melhem,Ewan R Pearson,Roberto Pola,Colin N A Palmer,Moneeza K Siddiqui
BACKGROUND AND AIMS The efficacy of statin therapy is hindered by intolerance to the therapy, leading to discontinuation. Variants in SLCO1B1, which encodes the hepatic transporter OATB1B1, influence statin pharmacokinetics, resulting in altered plasma concentrations of the drug and its metabolites. Current pharmacogenetic guidelines require sequencing of the SLCO1B1 gene, which is more expensive and
-
Risk of serious hypoglycaemia in patients with atrial fibrillation and diabetes concurrently taking antidiabetic drugs and oral anticoagulants: a nationwide cohort study. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-07-29 Huei-Kai Huang,Peter Pin-Sung Liu,Shu-Man Lin,Jih-I Yeh,Jin-Yi Hsu,Carol Chiung-Hui Peng,Kashif M Munir,Ching-Hui Loh,Yu-Kang Tu
AIMS Evidence regarding the risks of serious hypoglycaemia for patients with atrial fibrillation (AF) and diabetes mellitus (DM) taking antidiabetic medications with concurrent non-vitamin K antagonist oral anticoagulants (NOACs) vs. warfarin is limited. This study aimed to investigate this knowledge gap. METHODS AND RESULTS This retrospective cohort study used nationwide data from Taiwan's National
-
Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-09-20 Davide Stolfo,Lars H Lund,Gianfranco Sinagra,Felix Lindberg,Ulf Dahlström,Giuseppe Rosano,Gianluigi Savarese
BACKGROUND Guideline recommendations for the treatment of heart failure with mildly reduced ejection fraction (HFmrEF) derive from small subgroups in post-hoc analyses of randomized trials. OBJECTIVES We investigated predictors of renin-angiotensin system inhibitors/angiotensin receptor neprilysin inhibitors (RASI/ARNI) and beta-blockers use, and the associations between these medications and mortality/morbidity
-
Sodium-glucose cotransporter-2 inhibitors compared with glucagon-like-peptide-1 receptor agonists and out-of-hospital cardiac arrest in type 2 diabetes: a nationwide nested case-control study. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-07-29 Yrsa Kolka Júlíusdóttir,Andrim Halili,Ruben Coronel,Fredrik Folke,Christian Torp-Pedersen,Gunnar Hilmar Gislason,Talip E Eroglu
AIMS Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) are antidiabetic drugs that have beneficial direct effects on the myocardium by impacting cardiac ion channels and exchangers that control cardiac electrophysiology. We investigated the relationship between SGLT-2is in comparison to glucagon-like peptide-1 receptor agonists (GLP-1as) and out-of-hospital cardiac arrest (OHCA) in individuals with
-
Sodium-glucose cotransporter 2 inhibitor use in early-phase acute coronary syndrome with severe heart failure. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-07-29 Koshiro Kanaoka,Yoshitaka Iwanaga,Michikazu Nakai,Yuichi Nishioka,Tomoya Myojin,Shinichiro Kubo,Katsuki Okada,Tatsuya Noda,Yasushi Sakata,Yoshihiro Miyamoto,Yoshihiko Saito,Tomoaki Imamura
AIMS Sodium-glucose cotransporter 2 inhibitor (SGLT2i) improves clinical outcomes in patients with heart failure (HF), but has limited evidence of SGLT2i use in early-phase acute coronary syndrome (ACS). We determined association of early SGLT2i use compared with either non-SGLT2i or dipeptidyl peptidase 4 inhibitor (DPP4i) use in hospitalized patients with ACS. METHODS AND RESULTS This retrospective
-
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-05-11 Juan Tamargo,Stefan Agewall,Claudio Borghi,Claudio Ceconi,Elisabetta Cerbai,Gheorghe A Dan,Péter Ferdinandy,Erik Lerkevang Grove,Bianca Rocca,Patrick Sulzgruber,Anne Grete Semb,Samuel Sossalla,Alexander Niessner,Juan Carlos Kaski,Dobromir Dobrev
Cardiovascular diseases (CVD) remain the leading cause of death worldwide and pharmacotherapy of most of them is suboptimal. Thus, there is a clear unmet clinical need to develop new pharmacological strategies with greater efficacy and better safety profiles. In this review, we summarize the most relevant advances in cardiovascular pharmacology in 2022 including the approval of first-in-class drugs
-
Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-09-20 Paaladinesh Thavendiranathan,Christian Houbois,Thomas H Marwick,Tiffanie Kei,Sudipta Saha,Kyle Runeckles,Flora Huang,Tamar Shalmon,Kevin E Thorpe,Rossanna C Pezo,Anca Prica,Dawn Maze,Husam Abdel-Qadir,Kim A Connelly,Joyce Chan,Filio Billia,Coleen Power,Kate Hanneman,Bernd J Wintersperger,Christine Brezden-Masley,Eitan Amir
BACKGROUND AND AIMS Anthracyclines can cause cancer therapy-related cardiac dysfunction (CTRCD). We aimed to assess whether statins prevent decline in left ventricular ejection fraction (LVEF) in anthracycline-treated patients at increased risk for CTRCD. METHODS In this multicenter double-blinded, placebo-controlled trial, patients with cancer at increased risk of anthracycline-related CTRCD (per
-
Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-07-29 Marco Valgimigli,Victor Aboyans,Dominick Angiolillo,Dan Atar,Davide Capodanno,Sigrun Halvorsen,Stefan James,Peter Jüni,Vijay Kunadian,Antonio Landi,Sergio Leonardi,Roxana Mehran,Gilles Montalescot,Eliano Pio Navarese,Josef Niebauer,Angelo Oliva,Raffaele Piccolo,Susanna Price,Robert F Storey,Heinz Völler,Pascal Vranckx,Stephan Windecker,Keith A A Fox
Multiple guidelines and consensus papers have addressed the role of antithrombotic strategies in patients with established coronary artery disease (CAD). Since evidence and terminology continue to evolve, the authors undertook a consensus initiative to guide clinicians to select the optimal antithrombotic regimen for each patient. The aim of this document is to provide an update for clinicians on best
-
Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-09-20 Victor Chien-Chia Wu,Chien-Hao Huang,Chun-Li Wang,Meng-Hung Lin,Ting-Yu Kuo,Chih-Hsiang Chang,Michael Wu,Shao-Wei Chen,Shang-Hung Chang,Pao-Hsien Chu,Cheng-Shyong Wu,Yu-Sheng Lin
BACKGROUND Chronic hepatitis C virus (HCV) infection is associated with increased cardiovascular risks. We aimed to investigate the impact of direct acting antiviral (DAA) on HCV-associated cardiovascular events. METHODS In this retrospective cohort study, patients with the diagnosis of chronic HCV were retrieved from multi-institutional electronic medical records, where diagnosis of HCV was based
-
Bivalirudin plus a high-dose infusion versus heparin in patients with acute coronary syndrome. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-02 Mattia Galli,Giuseppe Gargiulo,Stefano Benenati,Roxana Mehran,Dominick J Angiolillo
-
Use of methylphenidate is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nationwide nested case-control study. Eur. Heart J. Cardiovasc. Pharmacother. (IF 7.1) Pub Date : 2023-11-02 Talip E Eroglu,Andrim Halili,Anojhaan Arulmurugananthavadivel,Ruben Coronel,Lars Vedel Kessing,Emil Loldrup Fosbøl,Fredrik Folke,Christian Torp-Pedersen,Gunnar Hilmar Gislason
AIM Methylphenidate, a sympathomimetic drug prescribed to treat attention-deficit/hyperactivity disorder (ADHD), is associated with cardiovascular events, but few studies have explored the risk of out-of-hospital cardiac arrest (OHCA). We investigated whether methylphenidate use is associated with OHCA in the general population. METHODS AND RESULTS Using Danish nationwide registries, we conducted a